PCSK9 and cardiovascular disorder: Based on these observations and considering that PCSK9 inhibitors have been added in the most recent guidelines for managing hypercholesterolemic conditions [130], the ability of lupin peptides to inhibit HMGCoAR activity and PCSK9 signaling and upregulate LDLR protein levels imply that LDPs are attractive candidate for nutraceutical developments for promoting cardiovascular disease prevention.